Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Dear all, I had decided to spend time each day for 6 days to be available as much as possible, and to answer your questions. Thank you for your engagement during this important time for @CandelTx. It's now time for me to go completely back to the day-to-day job, focusing on…
The gross proceeds from the offering to Candel are approximately $92 million, before deducting underwriting discounts and commissions and other offering expenses. Candel intends to use the net proceeds from the offering to continue the development of its product candidates,…
What a week for @CandelTx l!
We removed the overhang of a big binary data read out based on convincingly reaching the primary endpoint in the phase 3 trial of #CAN-2409 in #prostate cancer, supported by consistent data for the secondary and supplemental endpoints.
The study has…
It is of strategic importance to the company to bring additional high-profile institutional investors on board, while our existing key investors continue to support us We are very pleased we achieved this. This is important external validation of the quality of our programs,…
